查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095187

即時分子診斷市場－全球市場預測（2026-2032年）

Point of Care Molecular Diagnostics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，即時分子診斷市場將成長至 128.2 億美元，複合年成長率為 5.96%。

主要市場統計數據
基準年 2025 85.4億美元
預計年份：2026年 90.2億美元
預測年份 2032 128.2億美元
複合年成長率 (%) 5.96%

即時分子診斷執行摘要

即時分子診斷技術正在改變醫院、急診中心、診所、藥房、門診部和分散式社區醫療機構的臨床決策，它將核酸擴增、症候群檢體和病原體快速檢測更便捷地送達患者身邊。與可能需要集中樣本運輸和批量處理的傳統實驗室工作流程不同，即時分子檢測能夠支持更快的診斷、更早的治療啟動、更合理地使用抗生素、控制感染並改善患者分診。此領域在呼吸道感染疾病、性行為感染、胃腸道疾病、醫療相關感染疾病、結核病、敗血症相關工作流程以及新興病原體監測方面尤其重要。除了臨床對快速、準確和可操作結果的需求外，盒式平台、等溫擴增、微流體技術、自動化樣本製備、連接性和方便用戶使用型檢測設計的進步也推動了即時分子診斷技術的應用。在中心檢查室之外進行的分子診斷必須保持分析可靠性，同時還要與實際臨床工作流程相契合，因此，監管要求、品管、保險報銷政策和人員培訓仍然是實施過程中面臨的主要挑戰。隨著醫療保健系統日益分散化、準備更加充分並更加重視精準醫療，即時分子診斷正成為連接檢查室檢測和即時病患管理的關鍵橋樑。即時分子檢測正在發生變革性變化。

人工智慧對分子診斷的累積影響

人工智慧 (AI) 透過改善決策支援、工作流程自動化、檢測結果解讀和人群層面的監測，正在提升即時分子診斷的策略價值。 AI 驅動的軟體能夠幫助臨床醫生根據症狀、當地流行病學、先前檢測記錄和抗菌藥物處方指南等因素，結合複雜的症候群來解讀檢測結果。在操作層面，機器學習支援儀器維護警報、錯誤模式檢測、品質監控、操作員輔助、庫存視覺化以及跨分散式檢查網路的工作負載最佳化。 AI 還透過識別叢集、追蹤陽性率趨勢以及將分子檢測數據與地理和臨床訊號整合，增強感染疾病監測能力。在檢測方法開發方面，計算方法正被用於支持引子和探針設計、變異監測以及In Silico特異性分析，從而幫助開發人員更快地應對病原體的進化。然而，AI 在即時分子診斷中的應用需要檢驗的演算法、透明的效能指標、網路安全措施、資料管治以及對臨床決策支援相關法規的遵守。由於診斷結果會影響治療、隔離和公共衛生措施，因此人工監督仍然至關重要。因此，人工智慧的累積影響不在於取代分子診斷專業知識，而是建構一個更智慧、更互聯、更具韌性的患者近距離檢測生態系統。

關鍵區域視角下的全球診斷技術應用

在亞太地區，由於人口眾多、都市區醫院不斷擴建、感染疾病負擔沉重以及醫療基礎設施投資等因素，對快速、分散式檢查的需求日益成長，即時分子診斷技術正蓬勃發展。該地區各國優先進行結核病、呼吸道感染疾病、性行為感染感染、登革熱和其他傳染病防治項目，而已開發國家則將患者現場分子診斷技術整合到急診和門診部。在歐洲，嚴格的臨床實驗室標準、抗菌藥物管理計畫、體外診斷醫療設備監管以及跨境公共衛生優先事項，正日益利用分散式分子檢測來支持感染控制和快速病患管理。北美地區的特點是擁有成熟的檢測網路、完善的法律規範、分子檢測的廣泛臨床應用，以及在急診科、藥房和診所的快速普及，這得益於與電子健康記錄的整合以及公共衛生報告的需求。在拉丁美洲，分子診斷的部署正透過公共衛生舉措、醫院現代化以及呼吸道病毒、結核病、愛滋病相關疾病和蟲媒傳染病分子診斷的可及性提升而逐步推進，但成本效益、保險報銷和基礎設施差異等因素影響著其實施。在非洲，由於需要對結核病、愛滋病、瘧疾、呼吸道疾病、抗生素抗藥性和集體爆發進行鑑別診斷，分散式分子診斷的臨床意義日益凸顯。其部署受到資金籌措模式、供應鏈韌性、通訊基礎設施、品質保證和人力資源開發等因素的影響。在中東，先進的醫院系統、緊急準備、數位醫療基礎設施以及對感染疾病監測的投資，為在重症患者和社區部署即時分子診斷平台創造了機會。在所有地區，最成功的項目都將技術選擇與疾病負擔、診療路徑、品管系統和國家診斷策略結合。

關於診斷政策和實施的關鍵小組見解

北約成員國正在加強生物安全、軍事醫學、緊急準備和可部署診斷能力，這凸顯了在民用和國防相關醫療保健環境中，強大、互聯且快速的分子診斷平台的重要性。在七國集團（G7）國家，分子診斷在醫院、門診部、公共衛生實驗室和分散式醫療機構中廣泛應用，其重點在於快速臨床決策、應對疫情、品管系統和診斷管理。金磚國家（BRICS）大規模的患者群體、不斷擴大的國內診斷能力、優先應對結核病和呼吸系統疾病、對抗生素抗藥性的擔憂以及對醫療保健服務投入的增加。然而，各國在法律規範、保險報銷和基礎設施成熟度方面存在相當大的差異。歐盟（EU）強調統一的品質標準、抗抗生素抗藥性措施、體外診斷醫療設備的監管、醫療保健數據的互通性以及跨境公共衛生合作，為以臨床主導的分散式分子檢測提供了至關重要的環境。在東南亞國協，即時分子診斷正被優先考慮，以加強感染疾病防控，改善主要都市區醫院以外地區的醫療服務可及性，並支持呼吸道病原體、結核病、登革熱的鑑別診斷以及性行為感染感染的快速檢測。海灣合作理事會（GCC）國家的醫療衛生系統正將快速分子檢測納入急診醫學、旅行醫學和感染疾病控制項目，充分利用現代化的醫院基礎設施、數位健康舉措、旅行和大型集會健康措施以及公共衛生監測工作。在全部區域，政策協調、明確的報銷機制、監管信譽、互通性和人力資源發展是實現永續實施的關鍵因素。

主要國家即時分子診斷的發展趨勢

中國正在擴大國內診斷能力、完善醫院基礎設施和加強感染疾病監測，為呼吸系統疾病、結核病和醫院環境中的即時分子診斷平台奠定堅實基礎。在美國，受呼吸系統疾病、性行為感染感染和醫療相關感染疾病控制措施推動了其在醫院和門診的應用。同時，在印度，由於其龐大的患者群體、結核病負擔、呼吸系統疾病需求以及不斷擴展的公立和私立診斷網路，分散式分子檢測具有重要的臨床意義，但成本效益和實施品質仍然是重要的考慮因素。在德國，先進的醫院基礎設施、檢查室品質標準和感染控制重點正在支持其在急診、加護病房和門診環境中的應用。在英國，即時分子診斷技術正被應用於臨床管治、合理使用抗生素和整合式診療路徑的框架內，尤其是在呼吸系統疾病和急診醫學領域。在澳大利亞，即時分子診斷技術正被用於支持遠端醫療。在法國，快速診斷技術正透過醫院現代化、合理使用抗生素和公共衛生優先事項來推動。同時，在韓國，由於數位化醫療基礎設施、感染疾病控制系統和強大的診斷能力，互聯分子檢測平台正迅速整合到臨床和監測工作中。在義大利和西班牙，人們對呼吸系統檢測、敗血症相關工作流程、合理使用抗生素和分散式感染疾病控制的興趣持續成長。在加拿大，品質保證、公共衛生報告和地理分散的醫療保健至關重要，快速分子診斷技術不僅在偏遠和醫療服務不足的社區中發揮關鍵作用，而且在醫院分流中也發揮著重要作用。俄羅斯幅員遼闊，感染疾病監測需求龐大，凸顯了分散式分子檢測的重要性，尤其是在那些需要快速檢測結果以減少因前往中心實驗室而造成的延誤的地區。巴西大規模的醫療體系及其感染疾病的特徵也強烈表明，分散式分子檢測在呼吸道疾病、結核病和蟲媒病毒感染疾病的鑑別診斷以及醫院感染控制方面具有重要意義。墨西哥正透過公共和私人醫療投資擴大其分子檢測能力，並已建立呼吸道感染疾病、結核病和性行為感染感染的檢測流程，以支持其更廣泛的應用。

為行業領導者提供的實用建議

產業領導者應優先考慮經臨床驗證、易於整合的分子診斷解決方案，以應對呼吸道感染疾病診、合理使用抗生素、結核病檢驗、性性行為感染感染管理、醫療相關感染管理和集體爆發應對等高影響力應用情境。產品策略應強調易用性、最大限度減少人工操作時間、自動化樣本製備、可靠的污染控制、短檢測週期、清晰的結果解讀以及與電子健康記錄、實驗室資訊系統和公共衛生報告系統的整合。開發人員和醫療服務提供者應建立以診斷管理為中心的部署模式，以確保在正確的時間為正確的患者進行正確的檢測。監管合規計畫應儘早啟動，並包含可靠的分析檢驗、臨床效能證據、網路安全措施、可用性研究、風險管理和上市後監測。醫療系統應包括操作人員培訓、能力評估、品管、盡可能進行外部品質評估、結果解讀方案以及在分散式檢測項目中根據需要進行分散式檢查檢測的明確升級程序。與公共衛生機構、保險公司、醫院網路、學術機構和當地醫療服務提供者夥伴關係，有助於提高醫療服務的可近性和永續性。領導者還應投資於具有韌性的供應鏈、可擴展的生產能力、擴展的實驗室參數、服務支援以及支援監測且不損害患者隱私的人工智慧資料工具。將檢查室層級的效能與分散式系統的便利性、臨床證據、互通性和與醫療保健系統的整合相結合，將帶來最強大的競爭優勢。

基於證據的診斷結果的調查方法

本執行摘要採用系統的二手研究方法檢驗，重點關注來自權威公共衛生機構、監管機構、同行評審科學文獻、臨床實踐指南、衛生政策出版物、診斷管理研究途徑和診斷技術文件的、經驗證且有數據支持的行業洞察。分析著重闡述了即時分子檢驗領域已驗證的趨勢，包括臨床效用、監管考慮、推廣障礙、區域擴散模式、品管、互通性以及人工智慧的作用。資訊來源包括全球感染疾病控制重點、抗菌素抗藥性指南、診斷管理框架、體外診斷醫療設備的監管趨勢、檢查室品質標準以及分散式醫療機構中快速分子檢測的相關證據。調查方法排除了推測性的市場規模估算、市場佔有率計算、收入預測和未經證實的商業性聲明。研究結果經過定性整合，為醫療服務提供者、政策制定者、診斷技術開發商和相關人員提供可操作的建議。區域、群體和國家層面的觀點均從醫療基礎設施、疾病負擔、政策成熟度、公共衛生優先事項、法規環境和可近性等因素進行解讀。最終形成檢驗的執行摘要，旨在幫助人們從戰略角度理解即時分子診斷，而無需依賴未經證實的假設。

結論：分散式分子診斷的進展

即時分子診斷技術正成為現代醫療保健的重要組成部分，它能夠在患者身邊進行快速、準確且可操作的檢測。其價值不僅限於更快獲得檢測結果，還能支持感染控制、合理使用抗生素、緊急準備、分散式醫療保健、對抗抗生素抗藥性以及公共衛生監測。儘管該領域正透過自動化平台、多重檢測、數位化連接和人工智慧驅動的決策支援不斷進步，但其成功實施取決於監管合規性、臨床驗證、培訓、品質保證、網路安全、互通性和診斷管理。儘管區域和國家層面的採用情況反映了醫療保健優先事項、感染疾病負擔、基礎設施成熟度和政策環境的差異，但全球發展方向是明確的：患者身邊的分子檢測正從應急部署轉向常規融入臨床流程。能夠將創新與臨床證據、易用性、互通性和公平獲取相結合的產業領導者，將最有利於支持分散式分子診斷的下一階段發展。隨著醫療保健系統不斷要求更快、更準確的診斷決策，即時分子診斷將在具有韌性、互聯互通和以患者為中心的護理中發揮核心作用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 即時分子診斷市場：依產品類型分類

  • 裝置
  • 試劑和試劑盒
  • 軟體

第8章 即時分子診斷市場：依技術分類

  • 基因定序基礎
  • 雜合反應方法
  • 恒溫核酸增幅技術（INAAT）
  • 基於微陣列
  • 基於PCR的

第9章 即時分子診斷市場：依應用分類

  • 循環系統
  • 基因檢測
    • 職業篩檢
    • 新生兒篩檢
    • 產前檢查
  • 感染疾病
    • 胃腸道感染疾病
    • 呼吸道感染疾病
    • 性行為感染傳染病
    • 熱帶病
  • 腫瘤學
    • 液態切片
    • 突變譜分析
    • 致癌基因檢測

第10章：即時分子診斷市場：依最終用戶分類

  • 診所
  • 診斷檢查室
  • 居家醫療
  • 醫院

第11章 即時分子診斷市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第12章 即時分子診斷市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第13章 即時分子診斷市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • ACON LABS INC.
  • Becton, Dickinson and Company
  • Binx Health, inc.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Cardinal Health, Inc.
  • Chembio Diagnostics Inc.
  • Co-Diagnostics, Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • EKF Diagnostics Holdings
  • Exact Sciences Corporation
  • FHoffmann-La Roche AG
  • Genomadix Inc. by LuminUltra Technologies Ltd.
  • Grifols, SA
  • Henry Schein, Inc.
  • Hologic, Inc.
  • IDEXX Laboratories, Inc.
  • Johnson & Johnson Services, Inc.
  • Lumos Diagnostics
  • Meridian Bioscience, Inc.
  • Natera, Inc.
  • Novartis AG
  • OraSure Technologies, Inc.
  • Pfizer, Inc.
  • QIAGEN NV
  • Quidel Corporation
  • SD Biosensor
  • Sekisui Diagnostics
  • SHUWEN BIOTECH CO., LTD
  • Siemens Healthineers AG
  • Sonic Healthcare Limited
  • SYNLAB Group
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5A2C6AA669BE

The Point of Care Molecular Diagnostics Market is projected to grow by USD 12.82 billion at a CAGR of 5.96% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.54 billion
Estimated Year [2026] USD 9.02 billion
Forecast Year [2032] USD 12.82 billion
CAGR (%) 5.96%

Point of Care Molecular Diagnostics Executive Summary

Point of care molecular diagnostics is reshaping clinical decision-making by bringing nucleic acid amplification, syndromic testing, and rapid pathogen detection closer to patients across hospitals, urgent care centers, physician offices, pharmacies, ambulatory clinics, and decentralized community settings. Unlike conventional laboratory workflows that may require centralized sample transport and batching, point of care molecular testing supports faster diagnosis, earlier treatment initiation, antimicrobial stewardship, infection control, and improved patient triage. The field is particularly relevant for respiratory infections, sexually transmitted infections, gastrointestinal disease, healthcare-associated infections, tuberculosis, sepsis-related workflows, and emerging pathogen surveillance. Adoption is being driven by the clinical need for rapid, accurate, and actionable results, along with advances in cartridge-based platforms, isothermal amplification, microfluidics, automated sample preparation, connectivity, and user-friendly assay design. Regulatory expectations, quality management, reimbursement policies, and workforce training remain central to implementation, as molecular diagnostics performed outside central laboratories must maintain analytical reliability while fitting into real-world clinical workflows. As healthcare systems emphasize decentralization, preparedness, and precision medicine, point of care molecular diagnostics is becoming a critical bridge between laboratory-grade testing and immediate patient management. Transformative Shifts in Point of Care Molecular Testing

The point of care molecular diagnostics landscape is undergoing transformative shifts as healthcare providers move from centralized, reactive testing models toward distributed, near-patient diagnostic networks. Respiratory virus testing during recent public health emergencies demonstrated the value of rapid molecular results for triage, isolation decisions, and therapeutic selection, accelerating demand for compact, automated systems with simplified operation. At the same time, antimicrobial resistance has increased the need for fast pathogen identification and resistance marker detection to support evidence-based prescribing and infection prevention. Clinical workflows are also evolving from single-target assays toward multiplex molecular panels that can differentiate overlapping symptoms, especially in respiratory, gastrointestinal, and sexually transmitted infection testing. Digital connectivity is becoming a defining feature, enabling result reporting to electronic health records, laboratory information systems, public health systems, and surveillance networks. However, the shift is not purely technological. Successful deployment increasingly depends on quality assurance, competency assessment, contamination control, clinical governance, biosafety practices, and clear test utilization protocols. Health systems are balancing the convenience of decentralized molecular testing with the need to avoid unnecessary testing, control costs, and preserve diagnostic stewardship. These structural changes are positioning point of care molecular diagnostics as a foundational tool for faster care pathways, outbreak readiness, and patient-centered medicine.

Cumulative Impact of Artificial Intelligence on Molecular Diagnostics

Artificial intelligence is expanding the strategic value of point of care molecular diagnostics by improving decision support, workflow automation, assay interpretation, and population-level surveillance. AI-enabled software can help clinicians interpret complex syndromic results in the context of symptoms, local epidemiology, prior test history, and antimicrobial prescribing guidelines. In operational settings, machine learning can support instrument maintenance alerts, error pattern detection, quality monitoring, operator support, inventory visibility, and workload optimization across distributed testing networks. AI also enhances infectious disease surveillance by identifying clusters, tracking positivity trends, and integrating molecular test data with geographic and clinical signals. In assay development, computational approaches are being used to support primer and probe design, variant monitoring, and in silico specificity analysis, helping developers respond more rapidly to pathogen evolution. Nevertheless, AI adoption in point of care molecular diagnostics requires validated algorithms, transparent performance metrics, cybersecurity safeguards, data governance, and compliance with clinical decision-support regulations. Human oversight remains essential because diagnostic results influence treatment, isolation, and public health actions. The cumulative impact of AI is therefore not the replacement of molecular diagnostics expertise, but the creation of smarter, connected, and more resilient near-patient testing ecosystems.

Key Regional Insights Across Global Diagnostic Adoption

Asia-Pacific is experiencing strong momentum in point of care molecular diagnostics as large populations, urban hospital expansion, infectious disease burden, and investments in healthcare infrastructure increase demand for rapid decentralized testing. Countries across the region are prioritizing tuberculosis, respiratory infections, sexually transmitted infections, dengue, and other communicable disease programs, while advanced economies are integrating near-patient molecular diagnostics into emergency departments and outpatient care. Europe benefits from strong clinical laboratory standards, antimicrobial stewardship programs, in vitro diagnostic regulation, and cross-border public health priorities, with decentralized molecular testing increasingly used to support infection control and rapid patient management. North America is characterized by mature laboratory networks, established regulatory frameworks, broad clinical use of molecular testing, and growing deployment in urgent care, pharmacies, and physician office settings, supported by electronic health record integration and public health reporting needs. Latin America is advancing adoption through public health initiatives, hospital modernization, and improved access to molecular testing for respiratory viruses, tuberculosis, HIV-related care, and vector-borne diseases, although affordability, reimbursement, and infrastructure variability influence implementation. Africa shows high clinical relevance for decentralized molecular diagnostics due to tuberculosis, HIV, malaria differential diagnosis, respiratory disease, antimicrobial resistance, and outbreak response needs, with adoption shaped by funding models, supply chain resilience, connectivity, quality assurance, and workforce training. The Middle East is investing in advanced hospital systems, emergency preparedness, digital health infrastructure, and infectious disease surveillance, creating opportunities for point of care molecular platforms in high-acuity and community settings. Across all regions, the most successful programs align technology selection with disease burden, care pathways, quality systems, and national diagnostic strategies.

Key Group Insights for Diagnostic Policy and Adoption

NATO member countries are strengthening biosecurity, military medicine, emergency preparedness, and deployable diagnostic capabilities, supporting the relevance of rugged, connected, and rapid molecular platforms in both civilian and defense-related healthcare environments. G7 countries demonstrate advanced use of molecular diagnostics across hospitals, outpatient care, public health laboratories, and decentralized settings, with a focus on rapid clinical decision-making, pandemic readiness, quality systems, and diagnostic stewardship. BRICS countries represent diverse but significant adoption drivers, including large patient populations, domestic diagnostic capacity expansion, tuberculosis and respiratory disease priorities, antimicrobial resistance concerns, and increased investment in healthcare access; however, regulatory pathways, reimbursement, and infrastructure maturity vary widely. The European Union emphasizes harmonized quality standards, antimicrobial resistance strategies, in vitro diagnostic regulation, health data interoperability, and cross-border public health coordination, making it a key environment for clinically governed decentralized molecular testing. ASEAN countries are increasingly prioritizing point of care molecular diagnostics to strengthen infectious disease preparedness, improve access outside major urban hospitals, and support rapid detection of respiratory pathogens, tuberculosis, dengue-related differential diagnosis, and sexually transmitted infections. GCC healthcare systems are leveraging modern hospital infrastructure, digital health initiatives, travel and mass-gathering health preparedness, and public health surveillance agendas to integrate rapid molecular testing into emergency care, travel medicine, and infectious disease programs. Across these groups, policy alignment, reimbursement clarity, regulatory confidence, interoperability, and workforce readiness are decisive factors for sustainable adoption.

Key Country Insights in Point of Care Molecular Diagnostics

China is expanding domestic diagnostic capability, hospital infrastructure, and infectious disease surveillance, creating a substantial base for point of care molecular platforms in respiratory, tuberculosis, and hospital settings. The United States has broad clinical adoption of point of care molecular diagnostics across urgent care, emergency departments, physician offices, pharmacies, and decentralized care models, supported by demand for rapid respiratory, sexually transmitted infection, and healthcare-associated infection testing. Japan's aging population, advanced healthcare system, and strong infection control practices support use in hospitals and outpatient clinics, while India's high patient volumes, tuberculosis burden, respiratory disease needs, and expanding private and public diagnostic networks make decentralized molecular testing clinically important, though affordability and implementation quality remain key considerations. Germany's advanced hospital infrastructure, laboratory quality standards, and infection control priorities support adoption in emergency departments, intensive care, and outpatient settings. The United Kingdom applies near-patient molecular diagnostics within a framework of clinical governance, antimicrobial stewardship, and integrated care pathways, especially for respiratory disease and urgent care. Australia applies point of care molecular diagnostics to support remote care, emergency services, Indigenous health access, and public health response across wide geographies. France is advancing rapid diagnostics through hospital modernization, antimicrobial stewardship, and public health priorities, while South Korea's digitally advanced healthcare infrastructure, infectious disease preparedness, and strong diagnostic capabilities support rapid integration of connected molecular testing platforms into clinical and surveillance workflows. Italy and Spain show continued interest in respiratory testing, sepsis-related workflows, antimicrobial stewardship, and decentralized infectious disease management. Canada emphasizes quality-assured access, public health reporting, and geographically distributed care, making rapid molecular diagnostics valuable for remote and underserved communities as well as hospital-based triage. Russia's geographic scale and infectious disease surveillance needs support relevance for distributed molecular testing, particularly where rapid results can reduce delays from centralized laboratory access. Brazil's large healthcare system and infectious disease profile create strong relevance for decentralized molecular testing in respiratory illness, tuberculosis, arboviral differential diagnosis, and hospital infection control. Mexico is expanding molecular testing capacity through public and private healthcare investments, with respiratory infection, tuberculosis, and sexually transmitted infection workflows supporting broader use.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated, workflow-ready molecular diagnostic solutions that address high-impact use cases such as respiratory infection triage, antimicrobial stewardship, tuberculosis detection, sexually transmitted infection management, healthcare-associated infection control, and outbreak response. Product strategies should emphasize ease of use, minimal hands-on time, automated sample preparation, reliable contamination control, short turnaround time, clear result interpretation, and connectivity with electronic health records, laboratory information systems, and public health reporting systems. Developers and healthcare providers should build implementation models around diagnostic stewardship, ensuring the right test is used for the right patient at the right time. Regulatory planning must begin early, with robust analytical validation, clinical performance evidence, cybersecurity controls, usability studies, risk management, and post-market surveillance. For healthcare systems, decentralized testing programs should include operator training, competency assessment, quality control, external quality assessment where feasible, result interpretation protocols, and clear escalation pathways for confirmatory testing when needed. Partnerships with public health agencies, payers, hospital networks, academic institutions, and community care providers can improve access and sustainability. Leaders should also invest in resilient supply chains, scalable manufacturing, assay menu expansion, service support, and AI-enabled data tools that support surveillance without compromising patient privacy. The strongest competitive positioning will come from combining laboratory-quality performance with decentralized usability, clinical evidence, interoperability, and health system integration.

Research Methodology for Evidence-Based Diagnostic Insights

This executive summary is developed through a structured secondary research approach focused on verified, data-backed industry insights from credible public health agencies, regulatory authorities, peer-reviewed scientific literature, clinical practice guidance, healthcare policy publications, diagnostic stewardship frameworks, and diagnostic technology documentation. The analysis emphasizes validated trends in point of care molecular diagnostics, including clinical utility, regulatory considerations, implementation barriers, regional adoption patterns, quality management, interoperability, and the role of artificial intelligence. Sources considered include global infectious disease priorities, antimicrobial resistance guidance, diagnostic stewardship frameworks, in vitro diagnostic regulatory developments, laboratory quality standards, and evidence on rapid molecular testing in decentralized care settings. The methodology excludes speculative market sizing, market share calculations, revenue forecasting, and unsupported commercial claims. Insights are synthesized qualitatively to identify practical implications for healthcare providers, policymakers, diagnostic developers, and industry stakeholders. Regional, group, and country perspectives are interpreted through healthcare infrastructure, disease burden, policy maturity, public health priorities, regulatory environment, and access considerations. The result is an evidence-grounded executive summary designed to support strategic understanding of point of care molecular diagnostics without relying on unverified assumptions.

Conclusion: Advancing Decentralized Molecular Diagnostics

Point of care molecular diagnostics is becoming an essential component of modern healthcare by enabling rapid, accurate, and actionable testing near the patient. Its value extends beyond faster results, supporting infection control, antimicrobial stewardship, emergency preparedness, decentralized care access, antimicrobial resistance response, and public health surveillance. The landscape is advancing through automated platforms, multiplex assays, digital connectivity, and AI-enabled decision support, while implementation success depends on regulatory compliance, clinical validation, training, quality assurance, cybersecurity, interoperability, and diagnostic stewardship. Regional and country-level adoption reflects differing healthcare priorities, infectious disease burdens, infrastructure maturity, and policy environments, but the global direction is clear: near-patient molecular testing is moving from emergency-driven adoption toward routine integration in care pathways. Industry leaders that align innovation with clinical evidence, usability, interoperability, and equitable access will be best positioned to support the next phase of decentralized molecular diagnostics. As health systems continue to demand faster and more precise diagnostic decisions, point of care molecular diagnostics will play a central role in resilient, connected, and patient-centered care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Point of Care Molecular Diagnostics Market, by Product Type

  • 7.1. Introduction
  • 7.2. Instruments
  • 7.3. Reagents & Kits
  • 7.4. Software

8. Point of Care Molecular Diagnostics Market, by Technology

  • 8.1. Introduction
  • 8.2. Genetic Sequencing-based
  • 8.3. Hybridization-based
  • 8.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 8.5. Microarray-based
  • 8.6. PCR-based

9. Point of Care Molecular Diagnostics Market, by Application

  • 9.1. Introduction
  • 9.2. Cardiology
  • 9.3. Genetic Testing
    • 9.3.1. Carrier Screening
    • 9.3.2. Newborn Screening
    • 9.3.3. Prenatal Testing
  • 9.4. Infectious Disease
    • 9.4.1. Gastrointestinal Infections
    • 9.4.2. Respiratory Infections
    • 9.4.3. Sexually Transmitted Infections
    • 9.4.4. Tropical Diseases
  • 9.5. Oncology
    • 9.5.1. Liquid Biopsy
    • 9.5.2. Mutation Profiling
    • 9.5.3. Oncogene Panel

10. Point of Care Molecular Diagnostics Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Diagnostic Laboratories
  • 10.4. Home Care Settings
  • 10.5. Hospitals

11. Point of Care Molecular Diagnostics Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. Europe
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Africa
  • 11.6. Middle East

12. Point of Care Molecular Diagnostics Market, by Group

  • 12.1. NATO
  • 12.2. G7
  • 12.3. BRICS
  • 12.4. European Union
  • 12.5. ASEAN
  • 12.6. GCC

13. Point of Care Molecular Diagnostics Market, by Country

  • 13.1. China
  • 13.2. United States
  • 13.3. Japan
  • 13.4. India
  • 13.5. Germany
  • 13.6. United Kingdom
  • 13.7. Australia
  • 13.8. France
  • 13.9. South Korea
  • 13.10. Italy
  • 13.11. Canada
  • 13.12. Russia
  • 13.13. Brazil
  • 13.14. Mexico
  • 13.15. Spain

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. ACON LABS INC.
  • 15.3. Becton, Dickinson and Company
  • 15.4. Binx Health, inc.
  • 15.5. Bio-Rad Laboratories, Inc.
  • 15.6. bioMerieux SA
  • 15.7. Cardinal Health, Inc.
  • 15.8. Chembio Diagnostics Inc.
  • 15.9. Co-Diagnostics, Inc.
  • 15.10. Danaher Corporation
  • 15.11. DiaSorin S.p.A
  • 15.12. EKF Diagnostics Holdings
  • 15.13. Exact Sciences Corporation
  • 15.14. FHoffmann-La Roche AG
  • 15.15. Genomadix Inc. by LuminUltra Technologies Ltd.
  • 15.16. Grifols, S.A
  • 15.17. Henry Schein, Inc.
  • 15.18. Hologic, Inc.
  • 15.19. IDEXX Laboratories, Inc.
  • 15.20. Johnson & Johnson Services, Inc.
  • 15.21. Lumos Diagnostics
  • 15.22. Meridian Bioscience, Inc.
  • 15.23. Natera, Inc.
  • 15.24. Novartis AG
  • 15.25. OraSure Technologies, Inc.
  • 15.26. Pfizer, Inc.
  • 15.27. QIAGEN N.V.
  • 15.28. Quidel Corporation
  • 15.29. SD Biosensor
  • 15.30. Sekisui Diagnostics
  • 15.31. SHUWEN BIOTECH CO., LTD
  • 15.32. Siemens Healthineers AG
  • 15.33. Sonic Healthcare Limited
  • 15.34. SYNLAB Group
  • 15.35. Sysmex Corporation
  • 15.36. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENETIC SEQUENCING-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENETIC SEQUENCING-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENETIC SEQUENCING-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HYBRIDIZATION-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HYBRIDIZATION-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HYBRIDIZATION-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MICROARRAY-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MICROARRAY-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MICROARRAY-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PCR-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PCR-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PCR-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARRIER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARRIER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PRENATAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PRENATAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GASTROINTESTINAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROINTESTINAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTROINTESTINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TROPICAL DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TROPICAL DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TROPICAL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MUTATION PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MUTATION PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MUTATION PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOGENE PANEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONCOGENE PANEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOGENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 140. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 141. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 148. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 149. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. G7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 180. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 205. JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 206. JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 213. INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 214. INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 221. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 222. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. AUSTRALIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. AUSTRALIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. AUSTRALIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. AUSTRALIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. AUSTRALIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 237. AUSTRALIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 238. AUSTRALIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. AUSTRALIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 245. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 246. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. SOUTH KOREA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. SOUTH KOREA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. SOUTH KOREA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. SOUTH KOREA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. SOUTH KOREA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 254. SOUTH KOREA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. SOUTH KOREA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 261. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 262. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 293. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 294. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 305. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025